IL2 and breast cancer: 20 (14 ovarian, 6 BC) pts underwent a lymphodepleting regimen: fludarabine, cyclophosphamide, and, in 7 pts, 200 cGy total body irradiation (TBI). A haplo-identical NK-cell product IL-2 preactivated was infused s.c. IL-2 was given after infusion to promote expansion